A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine

Vaccine

Volumn 19, Issue 30, 2001, Pages 4143-4152

  Dagouassat, Nathalie ^a   Robillard, Virginie ^a   Haeuw, Jean François ^a   Plotnicky Gilquin, Helène ^a   Power, Ultan F ^a   Corvaı̈a, Nathalie ^a   Nguyen, Thien ^a   Bonnefoy, Jean Yves ^a   Beck, Alain ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Aluminium hydroxide; Aluminium phosphate; Antigen adsorption; BBG2Na; Respiratory syncytial virus

Indexed keywords

ADJU PHOS; ADJUVANT; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; CHIMERIC PROTEIN; ETHYLENE GLYCOL; GLYCOPROTEIN; PROTEIN BB; PROTEIN BBG2NA; PROTEIN G; PROTEIN G2NA; RECOMBINANT PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG;

ADSORPTION; AMINO ACID SEQUENCE; ARTICLE; BRONCHIOLITIS; CONTROLLED STUDY; ESCHERICHIA COLI; IMMUNOGENICITY; IONIC STRENGTH; ISOELECTRIC POINT; MOUSE; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

ADJUVANTS, IMMUNOLOGIC; ADSORPTION; ALUMINUM COMPOUNDS; ALUMINUM HYDROXIDE; AMINO ACID SEQUENCE; ANIMALS; BUFFERS; ETHYLENE GLYCOL; HYDROGEN-ION CONCENTRATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PHOSPHATES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0035919567     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00168-2     Document Type: Article

References (30)

1. Respiratory syncytial virus
2. Safety and immunogenicity of a recombinant subunit vaccine against RSV
3. Challenge of BALB/c mice with RSV does not enhance the Th2 pathway induced after immunisation with a recombinant G fusion protein, BBG2Na, in aluminium hydroxide
4. Protective immunity against RSV in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na
5. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a RSV G protein fragment
6. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant RSV subunit vaccine candidate
7. Influence of live RSV priming on the immune response generated by a recombinant vaccine candidate, BBG2Na
8. Synthesis and characterisation of RSV protein G related peptides containing two disulphide bridges
9. Identification of multiple protective epitopes (protectotopes) in the central conserved domain of a prototype human RSV G protein
10. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein
11. Vaccine adjuvants
12. Aluminium compounds as vaccine adjuvants
13. The antigenic value of toxoid precipitated by potassium alum
14. 26Al
15. Predicting the adsorption of proteins by aluminium-containing adjuvants
16. The importance of surface charge in the optimization of antigen-adjuvant interactions
17. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants
18. Adsorption of phosphate by aluminium hydroxycarbonate
19. Point of zero charge of amorphous aluminium hydroxide as a function of adsorbed carbonate
20. Treatment of aluminium hydroxide adjuvant to optimise the adsorption of basic proteins
21. Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants
22. The in vitro displacement of adsorbed model antigens from aluminium-containing adjuvants by interstitial proteins
23. De novo gene assembly using a paramagnetic solid support
24. Interactions in model vaccines composed of mixtures of aluminium-containing adjuvants
25. The serum albumin-binding domain of streptococcal protein G is a three-helical bundle: A heteronuclear NMR study
26. Solution structure of the immunodominant region of protein G of bovine RSV
27. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine
28. Combination vaccines: Issues in evaluation of effectiveness and safety
29. Development of combination vaccines